upneeq
Generic: oxymetazoline hydrochloride·Code: RVL-1201
upneeq: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RVL Pharmaceuticals plc (RVLP) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. ( 1 )(RVLP)
Frequently asked questions
Who is developing upneeq?
upneeq is being developed by RVL Pharmaceuticals plc.
What is upneeq's latest FDA decision?
The most recent tracked FDA decision for upneeq is Approval for 1 INDICATIONS AND USAGE UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. ( 1 ), dated July 8, 2020.
Get deeper analysis on upneeq
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis